The average one-year price target for Health In Tech (NasdaqCM:HIT) has been revised to $4.59 / share. This is an increase of 16.13% from the prior estimate of $3.95 dated December 3, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.54 to a high of $4.72 / share. The average price target represents an increase of 237.50% from the latest reported closing price of $1.36 / share.
What is the Fund Sentiment?
There are 23 funds or institutions reporting positions in Health In Tech. This is an increase of 10 owner(s) or 76.92% in the last quarter. Average portfolio weight of all funds dedicated to HIT is 0.00%, an increase of 1.08%. Total shares owned by institutions increased in the last three months by 203.83% to 1,167K shares.
What are Other Shareholders Doing?
Ancora Advisors holds 121K shares representing 0.27% ownership of the company.
Two Sigma Investments holds 120K shares representing 0.27% ownership of the company.
Geode Capital Management holds 116K shares representing 0.26% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
UBS Group holds 110K shares representing 0.24% ownership of the company. In its prior filing, the firm reported owning 127K shares , representing a decrease of 15.55%. The firm decreased its portfolio allocation in HIT by 47.61% over the last quarter.
Arete Wealth Advisors holds 67K shares representing 0.15% ownership of the company. In its prior filing, the firm reported owning 70K shares , representing a decrease of 4.84%. The firm increased its portfolio allocation in HIT by 206.01% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
